Each year new trends emerge in the pharma and biotech industry, often the result of new therapies born out of innovative technologies, regulatory changes, and the global economic climate. But despite all the business shifts, collaboration continues to propel drug portfolios from discovery through commercialization. For the third year, Pharma Intelligence and EBD Group continue their own collaboration to identify key trends around core elements of the partnering journey, by assessing the potential opportunities for currently unpartnered assets, revisiting the relationships built through in-person meetings at BIO-Europe, and analyzing the dealmaking activity from the last year. By combining data from Pharma Intelligence’s Medtrack and Strategic Transactions with anonymized meeting data from BIO-Europe 2017, this report demonstrates the ongoing appetite for alliances to share the risks intrinsic to drug development as well as the reward of hopefully bringing new treatments and cures to market. 
Produced in partnership with 